Prediction of the drug-drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

• Main Authors: Loeckie De Zwart (Author), Jan Snoeys (Author), Frank Jacobs (Author), Lilian Y. Li (Author), Italo Poggesi (Author), Peter Verboven (Author), Ivo Goris (Author), Ellen Scheers (Author), Inneke Wynant (Author), Mario Monshouwer (Author), Rao N. V. S. Mamidi (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid glycoprotein (AGP) and is primarily metabolized by cytoch...